Last reviewed · How we verify

Lupin, Inc. — Portfolio Competitive Intelligence Brief

Lupin, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lupin albuterol HFA MDI Lupin albuterol HFA MDI phase 3
Reference Product (Spiriva®) Reference Product (Spiriva®) phase 3 Long-acting muscarinic antagonist (LAMA) M3 muscarinic receptor Respiratory / Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  3. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 shared drug class
  6. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lupin, Inc.:

Cite this brief

Drug Landscape (2026). Lupin, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lupin-inc. Accessed 2026-05-14.

Related